Sociodemographic, health care, and clinical factors are associated with receipt of semaglutide in those with obesity but without diabetes.

Proteins are the workhorses that keep our cells running, and there are many thousands of types of proteins in our cells, each performing a specialized function. Researchers have long known that the ...

A complex molecular machine, the spliceosome, ensures that the genetic information from the genome, after being transcribed ...

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Ozempic and other GLP-1 agonists are helping millions with weight loss but concerns grow over their long-term effects. Recent ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

MS, an experimental protocol combining high-resolution protein fractionation using SDS-polyacrylamide gel electrophoresis (SDS-PAGE) with the latest mass spectrometry technology to enable highly ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Commercially available therapeutic lipidated GLP-1 analogues, semaglutide and ... to negatively impact the peptide solubility, in all cases, limiting it to a specific pH range. An increase in the ...